Introduction
============

The Functioning and Disability Supplement of the 2012 National Health Interview Survey estimated that 40 million US adults have pain every day or most days and another 87 million have pain on some days.[@b1-jpr-11-703] Many people with chronic pain also have low quality sleep, anxiety, depression, and poor overall health.[@b2-jpr-11-703] The annual economic cost of chronic pain is \$600 billion in the USA alone.[@b3-jpr-11-703] Prescription opioids are frequently used for chronic pain despite concerns about adverse events and addiction.[@b4-jpr-11-703] Opioid alternatives, including nonsteroidal anti-inflammatory drugs and antiepileptics, are also complicated by side effects[@b5-jpr-11-703],[@b6-jpr-11-703] and potential abuse.[@b7-jpr-11-703] Therefore, there is a need for nonpharmacological treatments for chronic pain.

Transcutaneous electrical nerve stimulation (TENS) is the delivery of electric current across the intact surface of the skin to activate sensory nerve fibers, primarily for pain relief.[@b8-jpr-11-703] TENS is characterized by a number of electrical parameters including the stimulation pulse shape, amplitude, duration, pattern, and frequency.[@b9-jpr-11-703] When evaluated with attention to methodological and technical factors,[@b10-jpr-11-703],[@b11-jpr-11-703] high frequency (\>50 Hz) TENS has been shown to be safe and effective in multiple forms of chronic pain.[@b11-jpr-11-703]--[@b16-jpr-11-703] However, it is likely that the efficacy of TENS in chronic pain has been adversely impacted by under dosing.[@b10-jpr-11-703],[@b17-jpr-11-703] General purpose TENS (GP-TENS) devices are designed to enable stimulation essentially anywhere on the body through individually wired electrodes. This is impractical for multisite chronic pain and complicates TENS use during daily activities and sleep.

A conceptual model for how sensory nerve stimulation leads to pain relief was proposed by Melzack and Wall[@b18-jpr-11-703] in 1965. Their theory stipulates that activation of large diameter sensory nerves (Aβ fibers) closes a "pain gate" in the spinal cord that inhibits the transmission of pain signals carried by nociceptive afferents (C and Aδ fibers) to the brain. In the past 20 years, anatomic pathways and molecular mechanisms that may underlie the pain gate have been identified. Sensory nerve stimulation activates the descending pain inhibition system, primarily the periaqueductal gray (PAG) and rostroventral medial medulla (RVM) located in the midbrain and medulla sections of the brainstem, respectively.[@b19-jpr-11-703] The PAG has neural projections to the RVM, which in turn has diffuse bilateral projections into the spinal cord dorsal horn[@b20-jpr-11-703],[@b21-jpr-11-703] that inhibit ascending pain signal transmission.[@b19-jpr-11-703]--[@b21-jpr-11-703] Enhanced central pain inhibition may also account for the benefits of sensory nerve stimulation in chronic pain of central nervous system origin.[@b22-jpr-11-703]

GP-TENS use is guided by the clinical practice of placing electrodes near the patient's pain.[@b23-jpr-11-703],[@b24-jpr-11-703] Stimulation directly over the site of pain may be optimal; however, it is not required. Alternative stimulation locations are effective,[@b25-jpr-11-703]--[@b27-jpr-11-703] including proximal to the site of pain,[@b22-jpr-11-703] distal to the site of pain,[@b28-jpr-11-703] on the contralateral limb,[@b29-jpr-11-703]--[@b31-jpr-11-703] within the same dermatomes as the pain,[@b32-jpr-11-703] and to unrelated spinal segments.[@b22-jpr-11-703],[@b33-jpr-11-703],[@b34-jpr-11-703] Widespread analgesia is likely related to spinal and supraspinal neural circuits that include activation of central pain inhibition.[@b22-jpr-11-703],[@b35-jpr-11-703]--[@b38-jpr-11-703] Additional mechanisms may include reduction in sympathetic tone,[@b39-jpr-11-703],[@b40-jpr-11-703] reversal of maladaptive changes in the central nervous system (CNS),[@b41-jpr-11-703] and functional interactions between the cardiovascular and pain regulation systems.[@b42-jpr-11-703] The potential for widespread analgesia suggests an alternative stimulation paradigm called fixed-site high-frequency TENS (FS-TENS), which is designed for a specific location rather than according to the patient's pain distribution. A priori knowledge on the anatomy and neurophysiology of a target site enables the development of wearable analgesic devices that are discreet and optimized for long-term, regular use without disrupting daytime activity or sleep. An FS-TENS device, placed on the upper calf, demonstrated clinically meaningful pain relief in an open-label, interventional study of 88 subjects with multisite chronic pain affecting the low back and lower extremities.[@b43-jpr-11-703]

Interventional studies in chronic pain, including randomized clinical trials, are generally conducted in structured settings on narrowly selected, homogeneous subjects. Although these studies can have good internal validity, lack of generalizability limits their application to real-world management of chronic pain.[@b44-jpr-11-703] Large-scale observational studies are needed to determine the effectiveness of chronic pain treatments. There have been a few substantial cross-sectional studies of TENS in chronic pain[@b45-jpr-11-703],[@b46-jpr-11-703] but no large longitudinal studies that examined changes in chronic pain measures in response to therapy. The present study evaluated the effectiveness of FS-TENS in a large heterogeneous chronic pain sample. The analyses were based on utilization and clinical data uploaded to an online database. The primary objective was to quantify changes in pain intensity and interference with function following 60 days of FS-TENS therapy. A secondary objective was to determine if FS-TENS utilization and pain relief exhibit a dose--response relationship.

Methods
=======

Study design
------------

This retrospective cohort study evaluated changes in chronic pain following 60 days of FS-TENS use. The study data were obtained from FS-TENS users who authorized uploading of their device utilization and clinical data to an online database via a mobile application. The analyses were conducted on an image of the database taken on September 22, 2017. All users of the FS-TENS device who agreed to the storage of their data in the database were eligible for the study. Inclusion criteria were users who provided demographic information and chronic pain characteristics and rated their pain intensity and interference with sleep, activity, and mood at baseline and after 60 days of use. [Figure 1](#f1-jpr-11-703){ref-type="fig"} depicts the data collection timeline. A valid baseline pain rating occurred on the first day (day 0) of device use or within the prior 6 days. A valid follow-up pain rating occurred between days 46 and 74 (ie, ±2 weeks of 60-day follow-up). If more than one pain rating was available within the baseline or follow-up window, the rating closest to day 0 or 60, respectively, was used. If more than one pain rating was available on day 0, the earliest was used. Exclusion criteria were an unspecified pain duration, a pain duration of \<3 months, an unspecified pain frequency, or a pain frequency less than several times a week.

By authorizing the storage of their data to the online database, device users consented to the manufacturer's privacy policy, which includes use of de-identified data for research purposes. This study was institutional review board exempt because the study authors used an image of the database without personal identifying information (Code of Federal Regulations, Title 45, Department of Health and Human Services, Part 46, Protection of Human Subjects, Section 101(b)(4)). The principles outlined in the World Medical Association Declaration of Helsinki -- Ethical Principles for Medical Research Involving Human Subjects -- were followed.[@b47-jpr-11-703] The reporting of this study is consistent with the STROBE guidelines.[@b48-jpr-11-703]

FS-TENS device
--------------

All FS-TENS users contributing to the database used the same over-the-counter device (Quell^®^; NeuroMetrix, Inc., Waltham, MA, USA).[@b43-jpr-11-703] The device includes a one-channel electrical stimulator, a stretchable band to secure the stimulator to the upper calf, and an electrode. The electrode is an array of hydrogel pads that provide a total stimulation surface area of 60 cm^2^. When located on the upper calf, the electrode array is circumferential and will stimulate sensory dermatomes S2-L4 independent of rotational placement. The stimulator generates bipolar, current-regulated pulses with alternating leading phase polarity. Stimulation has zero net current flow (DC) to prevent the development of polar ion concentrations with extended use that may cause skin reactions. The peak output voltage and current are 100 V and 100 mA, respectively. The pulse duration is either 200 or 280 µs. The interpulse intervals are random such that the mean stimulation frequency is 80 Hz.

Prior to first use, the device is calibrated to the user's sensation threshold by an algorithm using ascending and descending methods of limits. Subsequent stimulation is controlled automatically. The initial therapeutic level is set so that the pulse charge is 5 dB above sensation. This level is perceived as "strong but comfortable",[@b46-jpr-11-703] which is the sensation associated with effective high-frequency TENS.[@b14-jpr-11-703] The stimulation intensity is gradually increased by an algorithm to compensate for nerve de-sensitization and to activate deep tissue sensory afferents.[@b49-jpr-11-703] The user may also manually decrease or increase intensity. Each therapy session is 60 minutes, with sessions automatically starting every other hour. The device has a tri-axial accelerometer to monitor body orientation and movement, from which it determines when the user is sleeping using actigraphy methods.[@b50-jpr-11-703] During sleep, the stimulation intensity is reduced to lessen the likelihood of awakening.

The device communicates with a mobile application through Bluetooth^®^. The application is not required for therapeutic use of the device. It provides ancillary benefits including an indication of device status, creation of a demographic and clinical profile, tracking of pain ratings, visualization of device utilization and clinical data, and uploading of data to the online database. This study was based on the online database; therefore, all study subjects used the mobile application. However, the extent of use and impact on compliance and study outcomes were not evaluated.

FS-TENS database
----------------

The online FS-TENS database includes device utilization, demographics, chronic pain characteristics, daily pain ratings, and objective physiological measurements. All data are electively provided by device users. The origin of the data is either the device (utilization and physiological measurements) or the mobile application (demographics, pain characteristics, and pain ratings). This study evaluated device utilization, demographics, a subset of chronic pain characteristics, and pain ratings. Device utilization included the stimulation intensity measured in milliamps, the number of 1 hour therapy sessions each day, and the number of nights with device use. Demographics included the user's age, gender, height, and weight. Chronic pain characteristics included duration, painful health conditions, anatomic pain distribution, and frequency of pain. The choices for duration were "≤3 months", "\<1 year", "1--3 years", "3--10 years", "\>10 years", and "not sure". Painful health conditions were one or more among 16 medical conditions that are associated with chronic pain. Pain distribution was one or more among 11 sites. Pain was not qualified as unilateral or bilateral because of the potential for contralateral secondary hyperalgesia and allodynia.[@b51-jpr-11-703] Pain frequency was "every day or most days", "several times a week", "several times a month", or "not sure".

Pain intensity and interference were rated on an 11-point numerical rating scale derived from the Brief Pain Inventory -- Short Form.[@b52-jpr-11-703] The following four pain domains were assessed: average pain intensity over the past 24 hours, pain interference with sleep over the past 24 hours, pain interference with activity over the past 24 hours, and pain interference with mood over the past 24 hours. There was no schedule or requirement for device users to rate their pain.

Outcome measures and data analysis
----------------------------------

Device utilization, demographics, and pain characteristics were quantified by the mean and standard deviation (SD) if continuous and by frequency counts if categorical. Ninety-five percent confidence intervals (CIs) for frequency counts were determined using the modified Wald method. Although pain measures defined over a numerical rating scale are ordinal variables, they were treated as continuous variables for statistical analyses.[@b53-jpr-11-703],[@b54-jpr-11-703] The primary outcome measures were changes in pain intensity and pain interference from baseline to 60-day follow-up. The statistical significance of these changes was determined by the nonparametric Wilcoxon signed-rank test.

Dose--response associations were explored by stratifying subjects into three utilization subgroups based on the number of days they used their device, irrespective of the daily therapy session count. The maximum number of days was 61. The utilization cutoffs were prospectively set to 50 and 95% of the 60-day follow-up period. These levels were chosen to represent infrequent use (less than every other day) and daily use. Low utilization was defined as ≤30 days, intermediate utilization was defined as 31--56 days, and high utilization was defined as ≥57 days. Group differences among the three utilization subgroups were evaluated by one-way ANOVA and a two-sample *t*-test for post hoc analyses.

FS-TENS responders were defined for each of the pain domains. A pain intensity responder was a subject with ≥30% improvement from baseline to follow-up.[@b53-jpr-11-703],[@b55-jpr-11-703] Pain interference responders were subjects with comparable ≥2-point improvement from baseline to follow-up.[@b55-jpr-11-703] When reporting responder rates for a combination of two pain domains (eg, pain interference with activity or mood), subjects with a ≥2-point worsening in either of the same pain domains (eg, pain interference or mood) were excluded to address Type 1 errors due to multiple comparisons. All analyses were performed with Matlab Version R2017a (Mathworks, Natick, MA, USA).

Results
=======

Utilization and clinical data collected between January 2017 and September 2017 from 11,900 people using FS-TENS for chronic pain were evaluated. Out of this data set, baseline and 60-day follow-up pain ratings were available for 713 device users who formed the study cohort and are hereafter referred to as study subjects. The study cohort and the 11,187 excluded FS-TENS users differed with respect to female gender (52.3 vs 42.9%, *P*=0.0008, Pearson chi-squared test), body mass index (BMI) (30.3±7.0 vs 29.4±6.6, *P*=0.0021, two-group *t*-test), pain duration \>3 years (73.9 vs 62.0%, *P*\<0.0001, Pearson chi-squared test), number of painful health conditions (3.6±2.2 vs 2.9±2.0, *P*\<0.0001, two-group *t*-test), and number of pain sites (4.8±2.5 vs 4.0±2.4, *P*\<0.0001, two-group *t*-test). Among the excluded FS-TENS users, 2,478 (22%) users had a baseline pain rating. There were no statistically significant differences between these users and the study subjects with respect to baseline pain intensity or pain interference with sleep, activity, or mood.

[Table 1](#t1-jpr-11-703){ref-type="table"} lists the demographic and pain characteristics for the study cohort and for the subgroups stratified by FS-TENS utilization. The study subjects were generally older adults, overweight, and equally split among male and female gender. Most subjects reported chronic pain of \>3 years duration that was characterized by daily pain. More than 90% of subjects had moderate (44.2%, 4--6 points on 11-point numerical rating scale) or severe (47.1%, ≥7 points on 11-point numerical rating scale) pain at baseline. Subjects reported substantial pain interference with activity and mood, and somewhat less interference with sleep at baseline. As shown in [Table 2](#t2-jpr-11-703){ref-type="table"}, the study subjects had extensive pain-related medical histories. [Table 3](#t3-jpr-11-703){ref-type="table"} provides the anatomic distribution of pain sites. Nearly all subjects (97.2%) indicated low back and/or lower extremity pain. A substantial proportion (72.9%) also reported upper body pain (upper extremity, trunk, neck, head, or facial pain).

Stratification of the study cohort into utilization subgroups was not associated with clinically significant differences among demographic and pain characteristics ([Table 1](#t1-jpr-11-703){ref-type="table"}). BMI, pain duration, pain frequency, and pain interference with sleep at baseline exhibited statistically significant differences among the three subgroups by one-way ANOVA. The mean pain interference with sleep was higher for the low utilization subgroup when compared with the intermediate (*P*=0.0047) and high utilization subgroups (*P*=0.0149).

[Table 4](#t4-jpr-11-703){ref-type="table"} shows FS-TENS usage for the study cohort and for subjects stratified by utilization. On average, study subjects used FS-TENS on 73% of days and 32% of nights. The high utilization subgroup used FS-TENS daily. The low utilization subgroup used FS-TENS \~2 days per week on average. Except for stimulation intensity, there were statistically significant differences among the utilization subgroups. The number of sessions per day increased with higher utilization. As a result, total sessions were over fivefold greater for the high utilization subgroup (485) compared to the low utilization subgroup (88).

[Table 5](#t5-jpr-11-703){ref-type="table"} shows baseline to follow-up changes in pain measures. The average assessment period was 58.8 (SD 5.6) days. All pain measures exhibited a statistically significant decrease. The largest changes were observed for pain interference with activity and mood. The responder (ie, ≥30% improvement in pain intensity, ≥2 point improvement in pain interference) rates were 25.7% (CI 22.6--29.0%) for pain intensity, 32.4% (CI 29.1--35.9%) for pain interference with sleep, 39.4% (CI 35.9--43.0%) for pain interference with activity, and 40.1% (CI 36.6--43.8%) for pain interference with mood. A total of 48.7% of subjects were responders for pain interference with activity or mood. Changes in pain intensity, pain interference with activity and pain interference with mood exhibited statistically significant differences among the utilization subgroups. The responder rates for the high utilization subgroup were 34.5% (CI 28.7--40.7%) for pain intensity, 38.7% (CI 32.7--45.0%) for pain interference with sleep, 46.6% (CI 40.4--53.0%) for pain interference with activity, and 51.7% (CI 45.4--57.9%) for pain interference with mood. A total of 57.1% of subjects were responders for pain interference with activity or mood.

Discussion
==========

This retrospective observational study investigated the effectiveness of FS-TENS in a large heterogeneous chronic pain sample. The study data were obtained from an online database that aggregates utilization and clinical data from individuals with chronic pain using an FS-TENS device. The study cohort consisted of 713 subjects from a total of 11,900 eligible device users. Study subjects and excluded device users differed in several demographic and clinical features. The study cohort was more likely to be female, to have higher BMI, to have more pain sites, to have longer pain duration, and to have more painful health conditions. Given the large sample size, statistically significant differences among demographic and clinical characteristics were expected. However, the differences were small and suggest that the study subjects were comparable to the overall pool of eligible device users with respect to demographic and clinical variables.

Among the 11,187 device users who were not included in the study, 8,709 (78%) users did not have either a baseline or follow-up pain rating and 2,478 (22%) users had only a baseline pain rating and no follow-up rating. The small number of device users who provided baseline and follow-up pain ratings was expected. Although device users authorized sharing of their utilization and clinical data, and its use in research, they had no information about relevancy of specific data. Device users have the option to track their pain using the mobile application. The benefits of doing so include self-management and facilitation of communication with their physician. However, this feature is elective and is not yet utilized by most device users. Moreover, those who rate their pain do so with variable frequency and timing. The low utilization of pain tracking is likely related to mobile application engagement issues that challenge digital health interventions.[@b56-jpr-11-703]

It is reasonable to assume that device users who did not obtain pain relief, who had technical issues (eg, difficulty using the device), or who experienced side effects (eg, skin irritation) during the assessment period were more likely to discontinue therapy than those with positive results. Moreover, device users had a financial incentive to draw an early therapeutic conclusion to comply with a 60-day product return policy. For this reason, the study cohort may be enriched with FS-TENS responders. The extent of this selection bias cannot be quantified. Therefore, the study findings are generalizable to people with chronic pain completing 2 months of FS-TENS use and not necessarily to all who try FS-TENS. This interpretation is analogous to enriched enrollment randomized withdrawal design, which is common in chronic pain treatment trials.[@b57-jpr-11-703] In these studies, a lead in titration phase precedes randomization to active or placebo, such that randomization is performed only on responders.

Key strengths of this study were the real-world setting, large sample size, and heterogeneous distribution of chronic pain. These attributes increase the external validity of the study results. One benefit of evaluating an intervention in a real-world environment is that its use is overlaid on other pharmacological and nonpharmacological therapies. As such, the practical benefits of the intervention were assessed. To our knowledge, this is the largest study investigating longitudinal changes in pain measures in response to TENS therapy. With few exceptions,[@b45-jpr-11-703],[@b46-jpr-11-703],[@b58-jpr-11-703] experimental and observational studies of TENS in chronic pain have typically had small sample sizes.[@b10-jpr-11-703] A large sample size increases the statistical power to identify relevant outcomes.

Another strength of this study was the quantitative tracking of device utilization. Lack of compliance with self-administered TENS has been identified as a source of bias that may lead to the underestimation of treatment effects.[@b10-jpr-11-703],[@b17-jpr-11-703] Poor compliance may include inadequate stimulation intensity[@b10-jpr-11-703],[@b59-jpr-11-703] and insufficient duration and frequency of stimulation sessions.[@b10-jpr-11-703] The FS-TENS device used in this study addressed these issues through a calibration procedure that establishes a stimulation intensity within the therapeutic window (ie, "strong but comfortable" sensation) and with fixed 1 hour stimulation sessions that automatically start every other hour. In addition, utilization variables including stimulation intensity and daily therapy sessions were electronically monitored.

Study cohort characteristics
----------------------------

The study cohort reported a mean of 4.8 (SD 2.5) pain sites, which is consistent with recent studies showing that most chronic pain sufferers have widespread pain.[@b1-jpr-11-703],[@b60-jpr-11-703],[@b61-jpr-11-703] Multisite pain is associated with substantial comorbidity[@b60-jpr-11-703],[@b62-jpr-11-703]--[@b65-jpr-11-703] and greater health care utilization.[@b66-jpr-11-703] Nearly all (97%) study subjects reported low back and/or lower extremity pain. A high number (73%) of study subjects also reported upper body pain. Anatomically distributed chronic pain represents a practical challenge to treatment with GP-TENS because of the need to place electrodes on multiple body sites. In a recent study, the presence of multisite chronic pain predicted a poor clinical response to GP-TENS.[@b67-jpr-11-703] The present study suggests that FS-TENS may be an effective option for multisite chronic pain.

The study cohort represented a heterogeneous sample of chronic pain. Subjects reported a mean of 3.6 (SD 2.2) painful health conditions. Only 125 (17.5%) subjects reported a single condition, and 461 (64.7%) subjects reported three or more conditions. Arthritis, herniated disc, spinal stenosis, prior back injury, and fibromyalgia were each identified by at least 25% of the subjects. These disorders are commonly associated with chronic pain and have generally been shown to be responsive to TENS.[@b22-jpr-11-703],[@b58-jpr-11-703],[@b68-jpr-11-703]--[@b71-jpr-11-703] The generic use of the term "arthritis" did not enable a more detailed evaluation of the benefits of FS-TENS in specific arthritic conditions. We speculate, based on population prevalence,[@b72-jpr-11-703] that most subjects reporting arthritis had osteoarthritis. More specificity in arthritis categories will be beneficial for future studies. Complex regional pain syndrome (CRPS) was reported with a substantially higher frequency than its population prevalence.[@b73-jpr-11-703] CRPS is a complex entity that includes inflammatory, sympathetic, neuropathic, immune, and CNS abnormalities[@b74-jpr-11-703] and is difficult to treat. Although few studies of TENS in CRPS have been conducted, there is an indication of potential benefit.[@b75-jpr-11-703],[@b76-jpr-11-703]

The high rate of restless leg syndrome (RLS) reported by the study cohort (20%) requires comment. Although RLS is classified as a sleep disorder, the sensory symptoms are often described as painful.[@b77-jpr-11-703],[@b78-jpr-11-703] It is unclear whether RLS was a primary target of FS-TENS therapy or a common comorbidity. RLS is associated with multisite chronic pain,[@b79-jpr-11-703] diabetic neuropathy,[@b80-jpr-11-703] lumbosacral radiculopathy,[@b81-jpr-11-703] muscloskeletal pain,[@b82-jpr-11-703] and fibromyalgia.[@b83-jpr-11-703] Periodic leg movements are common in chronic pain[@b84-jpr-11-703] and a biomarker for RLS. There is preliminary evidence that TENS is useful in RLS.[@b85-jpr-11-703] A recent open-label pilot study of FS-TENS in RLS yielded encouraging results.[@b86-jpr-11-703] TENS has also been shown to reduce spinal excitability,[@b87-jpr-11-703] which is thought to be a neurophysiological mechanism underlying RLS.

FS-TENS effectiveness
---------------------

The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommends consideration of six outcome domains when designing studies evaluating chronic pain therapies. These domains are pain, physical function, emotional function, ratings of improvement and satisfaction with treatment, symptoms and adverse events, and subject disposition.[@b88-jpr-11-703] In most clinical studies of chronic pain treatments, pain intensity is the primary outcome measure. However, the most important treatment objective for chronic pain sufferers may not be a reduction in pain intensity.[@b89-jpr-11-703] Enhanced quality of life such as better sleep, greater activity, improved mood, reduced use of pain medications, and fewer side effects may have more practical relevance. Subjects with chronic pain use TENS in various ways in an attempt to improve their quality of life.[@b90-jpr-11-703] This apportioning of the beneficial effects of TENS across multiple pain domains may complicate efforts to demonstrate its efficacy.[@b10-jpr-11-703] In this study, FS-TENS effectiveness was assessed by changes in pain intensity and pain interference with sleep, activity, and mood measured on an 11-point numerical rating scale. The available data did not include a global assessment such as the Patient Global Impression of Change (PGIC)[@b88-jpr-11-703] or changes in analgesic use.

The results from this study advance our understanding of the impact of FS-TENS on chronic pain. Two months of FS-TENS use resulted in statistically significant reductions in average pain intensity and pain interference with sleep, activity, and mood. The magnitude of the group changes ranged from 0.4 points for pain interference with sleep to 1 point for pain interference with activity and mood. These results reflect real-world use of self-administered FS-TENS as one component of the subject's pain management program. The recorded changes may not reflect all the benefits of FS-TENS in this cohort. Global impression, satisfaction, additional psychological outcomes such as catastrophizing, and pain medication use may have improved but were not represented in the online database. The group changes in pain interference with activity and mood were at the 1-point level that is considered clinically meaningful.[@b55-jpr-11-703] In the responder analysis, 49% of subjects achieved a clinically important reduction in pain interference with activity or mood. Although the group changes in pain intensity and pain interference with sleep were modest, some subjects experienced clinically relevant improvement as indicated by the responder analysis. Small group differences may represent substantial clinical benefit to some subjects.[@b91-jpr-11-703]

The finding that FS-TENS has a greater influence on pain interference than on pain intensity is consistent with prior studies[@b43-jpr-11-703],[@b90-jpr-11-703] and relevant to establishing therapeutic expectations and design of future clinical studies. Therapy expectations may influence the outcome of chronic pain interventions, including TENS. Subjects primarily expecting substantial reductions in pain intensity may be disappointed and deem the therapy to be ineffective. By contrast, those focusing on changes in quality of life may consider the therapeutic impact to be substantial. Most randomized and observational studies of TENS therapy in chronic pain have used changes in pain intensity as the primary outcome measure.[@b10-jpr-11-703] This narrow focus may have contributed to low fidelity studies and uncertainty regarding the clinical effectiveness of TENS.[@b90-jpr-11-703]

The magnitude and pattern of changes in pain measures in this study are generally similar to an open-label, 60-day interventional study of the same FS-TENS device in 88 subjects with multisite chronic pain.[@b43-jpr-11-703] In that study, 81% of participants reported that their chronic pain improved based on a 5-point PGIC measure. Among those who reported improvement, 80% indicated a reduction in concomitant use of pain medications compared to only 12% in those without improvement. We cannot directly compare these results because the present study did not include a global impression or assessment of pain medication use. As in the current study, the impact on pain interference was greater than on pain intensity; however, the pattern differed. The largest reductions were in pain interference with activity, walking, and sleep, whereas the change in interference with mood was small. The reasons for the differences are unclear but may relate to the distribution of painful health conditions. The prior study[@b43-jpr-11-703] had a higher percentage of subjects reporting diabetes. Painful diabetic neuropathy is associated with poor sleep quality.[@b92-jpr-11-703]

We are not aware of other published studies that directly evaluated FS-TENS. However, several studies had relevant methods. Dailey et al[@b22-jpr-11-703] evaluated the impact of a single TENS treatment on multiple outcome measures in patients with fibromyalgia. The electrodes were applied at either the cervical-thoracic junction or lumbar-sacral junction. The patient's pain threshold was assessed at the following three sites: the site of stimulation, the alternate stimulation site (eg, if cervical-thoracic stimulation, then assessed at lumbar-sacral junction), and over the anterior tibialis muscle on the leg. The two nonstimulation sites were intended to "assess for widespread effects of TENS outside the site of stimulation".[@b22-jpr-11-703] The study demonstrated increased pain thresholds both at and outside of the site of stimulation. The authors concluded that TENS has widespread effects by decreasing central excitability and activating central pain inhibition mechanisms. Rao et al[@b25-jpr-11-703] studied the relationship between electrode placement and pain relief in subjects with various forms of chronic pain, including peripheral neuropathy, radiculopathy, and musculoskeletal pain. Electrode locations included the site of pain, proximal to the site of pain, in the same dermatome, at a related trigger or motor point, at a contralateral site, and at a remote site unrelated to the pain. They did not find a correlation between electrode placement and degree of improvement.

FS-TENS dose--response relationship
-----------------------------------

A key finding from this study is the positive association between FS-TENS utilization and effectiveness. The baseline to follow-up improvement in all pain measures increased with higher device utilization. The number of subjects meeting the responder definition for pain interference with activity (33 vs 47%) and mood (25 vs 52%) increased substantially when comparing the low- and high-utilization subgroups. The proportion of subjects with a clinically important reduction in pain interference with activity or mood increased from 38 to 57%. Similarly, the pain intensity responder rate increased from 18% in the low-utilization subgroup to 33% of subjects in the high-utilization subgroup. FS-TENS utilization was determined by the subject rather than controlled. One explanation for this result is the existence of a causal link between FS-TENS dose and effectiveness. Another explanation is that users who benefited from FS-TENS, due to specific or nonspecific mechanisms, used it more often. In either case, it appears that daily, as opposed to intermittent, FS-TENS use provides individuals with chronic pain with the greatest likelihood of meaningful clinical benefit.

The dose--response behavior of TENS has not been studied extensively. Currently published evidence suggests that stimulation intensity directly influences the degree of analgesia in a dose-dependent fashion.[@b59-jpr-11-703],[@b93-jpr-11-703] Stimulation below the level of sensory perception does not produce analgesia, and the degree of analgesia is correlated to the stimulation intensity. To our knowledge, the present study is the first to show a relationship between the rate of daily TENS use and pain outcomes. Regular users of FS-TENS experienced better pain outcomes than those with less frequent use. Subjects using FS-TENS every day also used their device more during the day than those with lower utilization. As a result, the total number of therapy sessions in the high-utilization subgroup was five times greater than that in the low-utilization subgroup. High-frequency TENS is thought to cause transient hypoalgesia through the elevation of enkephalins and the activation of central pain inhibition.[@b19-jpr-11-703] In the present study, \>95% of subjects reported daily pain. It is possible that those who used their device on an intermittent basis did not experience the same level of pain relief as those who used it daily, due to inadequate dosing. Many TENS studies have used infrequent clinic-based therapy.[@b10-jpr-11-703] Those studies that sent subjects home with a TENS device typically did not have objective monitoring with which to evaluate compliance and utilization. It is probable that some prior TENS studies have been negatively impacted by under dosing.[@b10-jpr-11-703],[@b17-jpr-11-703],[@b94-jpr-11-703]

FS-TENS mechanism of action
---------------------------

The principle of widespread analgesia has led to the development of FS-TENS, where the device is designed for a specific location rather than according to the patient's pain distribution. A priori knowledge on the anatomy and neurophysiology of a target site enables the development of wearable analgesic devices that are discreet and optimized for extended use without disrupting daytime activity or sleep. This study re-enforces the effectiveness of FS-TENS in multisite chronic pain. It is unlikely that these results can be explained by a localized model of TENS analgesia. If the FS-TENS device was limited to providing focused pain relief in the legs, consistent with its upper calf location, then we must assume that this effect accounted for the entire observed improvement in pain outcomes. This explanation is unlikely. Leg pain accounted for only 18.4% (SD 18.0%) of the total number of pain sites among the study subjects, and 25% of subjects did not report any leg pain. Moreover, there were no statistically significant differences in baseline to follow-up changes in pain measures among high-utilization subjects with and without leg pain. A more plausible explanation is that a substantial portion of the FS-TENS benefit was from analgesia outside of the stimulation area, such as distally in the feet, proximally in the low back region, and possibly extra-segmentally in the upper body. These widespread analgesic effects are likely secondary to segmental mechanisms related to high-frequency stimulation of the S2 to L4 dermatomes and, more broadly, to activation of central pain inhibition.[@b19-jpr-11-703],[@b22-jpr-11-703]

Study limitations
-----------------

This study had several limitations that need to be considered when interpreting the results. First, the entire study cohort consisted of FS-TENS device users. There was no comparison group that did not receive active FS-TENS therapy. Therefore, the impact of nonspecific effects, such as placebo, cannot be reliably estimated. The observation of a strong dose--response association enhances the likelihood of a causal relationship between FS-TENS and widespread analgesia[@b95-jpr-11-703] but leaves the possibility that measured response is due to nonspecific effects. Controlled studies with randomization to standard and/or sham therapy will be helpful to further understand the mechanisms underlying FS-TENS analgesia. Second, pain outcomes were limited to those available in the database. A global impression of improvement and changes in analgesic use, which showed improvement in a prior study of FS-TENS,[@b43-jpr-11-703] were not available. As a result, the range of potential benefits of FS-TENS in the study cohort could not be determined. Third, it was not possible to quantify the number of users with a baseline pain rating who did not provide a follow-up pain rating due to the lack of FS-TENS effectiveness. Consequently, the impact of selection bias cannot be reliably estimated.

Conclusion
==========

The results from this study suggest that FS-TENS is an effective option for treating multisite chronic pain in a real-world setting. The most significant impact was a clinically meaningful reduction in pain interference with activity and mood. There were also statistically significant reductions in pain intensity and pain interference with sleep. Pain intensity and pain interference with activity and mood exhibited a dose--response association. These results further encourage the use of FS-TENS, in the form of wearable devices, for the treatment of chronic pain. The effectiveness of FS-TENS in multisite pain builds support for its widespread analgesic effects, likely arising from the activation of central pain inhibition.
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###### 

Demographics and pain characteristics of study cohort

  Characteristic                                   All (N=713)   Utilization subgroups   *P*-value                   
  ------------------------------------------------ ------------- ----------------------- ------------- ------------- --------
  Female, n (%)                                    373 (52.3)    74 (50.0)               179 (54.7)    120 (50.4)    0.3663
  Age (years), mean (SD)                           55.4 (13.7)   55.0 (14.7)             55.2 (13.8)   55.9 (13.1)   0.8028
  BMI (kg/m^2^), mean (SD)                         30.3 (7.0)    31.9 (8.0)              30.2 (7.1)    29.7 (6.2)    0.0305
  Duration of pain \>3 years, n (%)                527 (73.9)    103 (69.6)              236 (72.2)    188 (79.0)    0.0061
  Daily pain, n (%)                                691 (96.9)    143 (96.6)              311 (95.1)    237 (99.6)    0.0096
  Number of pain sites, mean (SD)                  4.8 (2.5)     4.8 (2.5)               4.8 (2.5)     4.9 (2.6)     0.7191
  Number of painful health conditions, mean (SD)   3.6 (2.2)     3.7 (2.4)               3.6 (2.3)     3.7 (2.2)     0.8998
  Baseline pain, mean (SD)                                                                                           
   Average pain                                    6.23 (1.95)   6.28 (2.02)             6.22 (1.95)   6.21 (1.91)   0.9491
   Sleep interference                              5.23 (2.94)   5.84 (2.84)             5.03 (3.01)   5.11 (2.87)   0.0151
   Activity interference                           6.61 (2.43)   6.93 (2.50)             6.60 (2.43)   6.43 (2.35)   0.1458
   Mood interference                               6.29 (2.63)   6.46 (2.67)             6.20 (2.67)   6.30 (2.55)   0.6039

**Notes:** Low, therapy on ≤30 days. Intermediate, therapy on 31--56 days. High, therapy on ≥57 days. *P*-value is for one-way ANOVA among the three utilization subgroups.

**Abbreviation:** SD, standard deviation.

###### 

Self-reported painful health conditions

  Condition, n (%)                    N=713
  ----------------------------------- ------------
  Musculoskeletal                     
   Arthritis                          444 (62.3)
   Fibromyalgia                       182 (25.5)
  Spinal                              
   Herniated disc                     217 (30.4)
   Spinal stenosis                    205 (28.8)
  Neuropathic                         
   Diabetes                           93 (13.0)
   Complex regional pain syndrome     168 (23.6)
   Shingles/post herpetic neuralgia   31 (4.3)
   Restless leg syndrome              143 (20.1)
   Multiple sclerosis                 20 (2.8)
  Previous injury                     
   Back                               290 (40.7)
   Neck                               160 (22.4)
   Arm/hand                           155 (21.7)
   Leg/foot                           13 (1.8)
  Cancer                              41 (5.8)
  Headaches/migraine                  176 (24.7)
  Others                              254 (35.6)

**Note:** More than one category per participant may apply.

###### 

Anatomical distribution of pain

  Location, n (%)          N=713
  ------------------------ ------------
  Lower extremity          641 (89.9)
   Feet/ankle              360 (50.5)
   Leg (including knees)   535 (75.0)
   Hips                    412 (57.8)
  Low back                 575 (80.6)
  Trunk (midsection)       164 (23.0)
  Upper extremity          478 (67.0)
   Hands/wrist             309 (43.3)
   Arms                    177 (24.8)
   Shoulders               375 (52.6)
  Neck                     359 (50.4)
  Head/face                117 (16.4)
  Others                   72 (10.1)

**Note:** More than one category per participant may apply.

###### 

FS-TENS therapy over 60-day assessment period

  Parameter, mean (SD)               All (N=713)   Utilization   *P*-value                   
  ---------------------------------- ------------- ------------- ------------- ------------- --------
  Number of days with ≥1 session     44.5 (16.1)   18.4 (8.1)    45.2 (7.4)    59.7 (1.4)    0.0000
  Number of nights with ≥1 session   19.6 (19.2)   5.4 (6.3)     16.2 (14.8)   33.1 (21.4)   0.0000
  Sessions/day                       6.3 (2.6)     4.5 (2.0)     5.8 (1.9)     8.1 (2.7)     0.0000
  Total number of sessions           301 (192)     88 (58)       264 (109)     485 (168)     0.0000
  Mean stimulation level (mA)        27.1 (14.0)   25.9 (12.9)   27.2 (14.0)   27.4 (14.6)   0.5840

**Notes:** Low, therapy on ≤30 days. Intermediate, therapy on 31--56 days. High, therapy on ≥57 days. *P*-value is for one-way ANOVA among the three utilization subgroups. Session, 1 hour continuous stimulation.

**Abbreviations:** FS-TENS, fixed-site high-frequency transcutaneous electrical nerve stimulation; SD, standard deviation.

###### 

Changes in pain measures from baseline to 60-day follow-up in FS-TENS users

  Pain measure, mean (SD)   All (N=713)                                               Utilization                                               *P*-value                                                                                                           
  ------------------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- --------
  Average pain              −0.37 (2.51)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.23 (2.60)                                               −0.31 (2.38)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −0.82 (2.54)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.0003
  Sleep interference        −0.31 (3.07)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.03 (3.18)                                               −0.22 (2.97)                                              −0.65 (3.13)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.0814
  Activity interference     −0.99 (2.69)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −0.51 (2.70)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −0.94 (2.63)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −1.36 (2.74)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.0019
  Mood interference         −1.02 (2.78)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −0.22 (2.73)                                              −0.97 (2.66)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   −1.58 (2.87)[\*](#tfn8-jpr-11-703){ref-type="table-fn"}   0.0000
  Follow-up (days)          58.78 (5.62)                                              58.97 (7.18)                                              58.20 (5.74)                                              59.47 (4.06)                                              0.0267

**Notes:** Low, therapy on ≤30 days. Intermediate, therapy on 31--56 days. High, therapy on ≥57 days. *P*-value is for one-way ANOVA among the three utilization subgroups.

Statistical significance of baseline to 60-day follow-up changes determined by Wilcoxon rank sum test, *P*\<0.05.

**Abbreviations:** FS-TENS, fixed-site high-frequency transcutaneous electrical nerve stimulation; SD, standard deviation.
